Six years lat­er, SEC drops claims of ac­count­ing fraud against biotech ex­ec

The US Se­cu­ri­ties and Ex­change Com­mis­sion has dropped its claims against the for­mer CEO of Osiris Ther­a­peu­tics, who was ac­cused of ly­ing about the re­gen­er­a­tive med­i­cine play­er’s fi­nan­cial per­for­mance.

All claims against Lode De­bra­ban­dere have been dis­missed, ac­cord­ing to a court fil­ing from late No­vem­ber, cap­ping a le­gal saga that goes all the way back to 2017.

“The SEC’s al­le­ga­tions had no mer­it, and the com­plete dis­missal is the on­ly cor­rect, fair, and just out­come,” De­bra­ban­dere wrote in an email to End­points News. “I am grate­ful that the SEC ul­ti­mate­ly rec­og­nized it should drop the ac­tion against me.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN